新型类嘌呤脱氧核糖核苷类化合物的合成

以1,3,5-三-O-苯甲酰基-2-脱氧-2-β-氟-α-D-核糖为原料,通过溴代、与4-氯吡咯[2,3-d]嘧啶的钠盐偶合、4-氯的氨基化等反应,设计合成了一系列具有新型结构的4-取代-9-(2′-脱氧-2′-β-氟-β-D-呋喃糖基)吡咯[2,3-d]嘧啶类化合物,其化学结构经核磁共振、高分辨率质谱分析确证;并且初步探讨了反应条件和反应机理.结果表明,以无水四氢呋喃为溶剂,密闭高压回流反应,反应产率较高.     

2,5,6-位正交保护的5-氧-(喹啉-2-甲酰基)-β-D-半乳呋喃糖乙硫苷供体的合成

以D-半乳糖为原料,通过苯甲酰化、硫苷化、异亚丙基化、喹啉-2-甲酰化等10步反应首次合成了2,5,6-位正交保护的5-氧-(喹啉-2-甲酰基)-β-D-半乳呋喃糖乙硫苷供体10,总收率为18.6%,其结构经1H NMR,13C NMR和LC-MS(ESI)确证。在优化化合物5,8,9的合成工艺过程中,首创了用硅胶柱的弱酸性脱除半乳呋喃糖5,6-位异亚丙基的方法。发现在-15℃的低温条件下,通过分批加入叔丁基二甲基硅基三氟甲磺酸酯(TBSOTf),可以得到半乳呋喃糖6-位被叔丁基二甲基硅基(TBS)选择性保护的单一产物。     

一种新的保护的2-脱氧-2-氨基葡二糖合成

以氨基葡萄糖盐酸盐为原料制得糖基给体3,4,6-三-氧-乙酰-2-脱氧-2-(2,2,2-三氯乙氧)甲酰胺基-α-D-吡喃葡萄糖基三氯乙酰亚胺酯(5)和糖基受体烯丙基-4,6-氧-亚苄基-2-脱氧-2-(2,2,2-三氯乙氧)甲酰胺基-α-D-吡喃葡萄糖苷(7).在三甲基硅基三氟甲基磺酸酯(TMSOTf)条件下,给体5与受体7反应得到一种新的二糖烯丙基-3,4,6-三-氧-乙酰-2-脱氧-2-(2,2,2-三氯乙氧)甲酰胺基-β-D-吡喃葡萄糖-(1→3)-4,6-氧-亚苄基-2-脱氧-2-(2,2,2-三氯乙氧)甲酰胺基-α-D-吡喃葡萄糖糖苷(10),收率为39.2%.当7在无水BaO和Ba(OH)2·8H2O的条件下与BnBr进行3-OH苄基化反应时,却得到了烯丙基-3-氧-苄基-4,6-氧-亚苄基-2-脱氧-2-羟甲酰胺基-α-D-吡喃葡萄糖苷(8).改用Ag2O条件下与BnBr进行苄基化,得到预期的烯丙基-3-氧-苄基-4,6-氧-亚苄基-2-脱氧-2-(2,2,2-三氯乙氧)甲酰胺基-α-D-吡喃葡萄糖苷(9),从而避免了氨基保护基三氯乙氧甲酰基的水解.标题化合物10对枯草芽孢杆菌、葡伎根霉等微生物有一定的抑制作用.     

合成奈拉滨C-1位α-异构体的新方法

报道了一种合成奈拉滨C-1位α-异构体——2-氨基-6-甲氧基-9-α-D-阿拉伯糖呋喃糖基-9H-嘌呤(7α)的新方法。以D-阿拉伯糖为原料,经醚化,乙酰化和取代3步反应制得中间体1,2,3,5-O-四乙酰基-D-阿拉伯呋喃糖苷(4);4与甲氧基修饰的嘌呤经Vorbrüggen偶联反应后脱保护基合成了7α,其结构经1H NMR确证。     

抗肿瘤药物卡培他滨的合成工艺改进

本文以价廉易得的D-核糖为起始原料,经缩酮化保护、磺酰化,1,4-二氧六环做溶剂的条件下,使用硼氢化钾还原、再经水解、乙酰化反应得到关键中间体1,2,3-三-O-乙酰基-5-脱氧-D-呋喃核糖,再与5-氟胞嘧啶进行Silyl反应制备5′-脱氧-2′,3′-二-O-乙酰基-5-氟胞苷,与氯甲酸正戊酯进行酰胺化,水解得到目标化合物卡培他滨(1),结构经¹HNMR、¹³CNMR以及MS表征,总产率49.69%(以D-核糖计),HPLC测得纯度100.00%。该合成方法原料廉价易购、反应条件温和,改进后的路线操作简单,绿色环保,适合工业化生产。     

5-卤代-2’-脱氧-2’-β-氟-4’-叠氮嘧啶核苷的合成与抗乙肝病毒活性研究

以(间氯)苯甲酰基保护的2’-脱氧-2’-β-氟-4’-叠氮尿苷为起始原料,经过硝酸铈铵(CAN)介导的卤代、三氮唑活化、胺化、脱保护合成了一系列5-卤代的2’-脱氧-2’-β-氟-4’-叠氮嘧啶核苷类化合物.体外生物活性评价研究表明, 5-氯代(6a)和5-碘代(6c)核苷衍生物具有很好的抗乙肝病毒活性,而且细胞毒性较小.     

烟酰胺腺嘌呤二核苷酸类CD38抑制剂的合成及生物活性评价

分别以1,3,5-三苯甲酰基-α-D-核糖、3,5-二苯甲酰基-2-脱氧-2,2-二氟戊呋喃糖-1-酮和D-木糖为原料, 经由烟酰胺核苷及烟酰胺核苷酸中间体, 合成了系列糖环经氟原子取代的烟酰胺腺嘌呤二核苷酸(NAD)类CD38抑制剂. 基于对CD38的水解抑制能力的考察, 评价了所合成氟代NAD类似物的活性. 结果表明, 糖环上氟原子取代的数目和位置对抑制剂活性的影响十分明显, 烟酰胺核苷的端基构型对活性的影响较大. 2个化合物均显示出非常好的CD38抑制活性, 其中化合物2a的抑制活性高出阳性对照物阿糖型氟代烟酰胺腺嘌呤二核苷酸2个数量级.     

伊格列净的合成

以苯并噻吩和2-氟-5-溴苯甲醛为原料,经过加成,还原得到中间体2-(5-溴-2-氟苄基)苯并噻吩,该中间体与2,3,4,6-四-O-三甲基硅烷基-D-吡喃葡萄糖酸-1,5-内酯经缩合,甲醚化,还原得目标化合物伊格列净,总收率50.12%,纯度98.71%,其结构经1H NMR及MS确证。     

3-叠氮基丙基-β-D-吡喃半乳糖苷的合成工艺改进

以D-半乳糖为原料,经苯甲酰化制得1,2,3,4,6-五-氧-苯甲酰基-β-D-吡喃半乳糖苷(2);2与3-氯丙醇在三氟化硼乙醚作用下进行糖苷化反应制得3-氯丙基-2,3,4,6-四-氧-苯甲酰基-β-D-吡喃半乳糖苷(3);3与叠氮钠反应制得3-叠氮基丙基-2,3,4,6-四-氧-苯甲酰基-β-D-吡喃半乳糖苷(4);4在甲醇钠作用下脱苯甲酰基合成了3-叠氮基丙基-β-D-吡喃半乳糖苷,总收率67.8%,其结构经1H NMR和ESI-HR-MS确证。     

无溶剂、无催化剂条件下α-腺嘌呤阿拉伯糖苷的合成

为了发展有效合成α-腺嘌呤阿拉伯糖苷的方法,以1,2,3,5-四-O-乙酰基-β-D-阿拉伯糖和6-氯嘌呤为原料,在微波辐射和无溶剂、无催化剂条件下反应得到中间体9-α-D-(2',3',5'-三-O-乙酰基)阿拉伯呋喃糖基-6-氯嘌呤,收率85%。该中间体物在Na2CO3催化下脱除乙酰基,然后"一锅"加入饱和的NH3/CH3OH溶液氨解,以90%的收率得到α-腺嘌呤阿拉伯糖苷。关键中间体9-α-D-(2',3',5'-三-O-乙酰基)阿拉伯呋喃糖基-6-氯嘌呤的合成反应规模可以扩大到100 g。类似地合成α-2-氟腺嘌呤阿拉伯糖苷和α-2-氨基腺嘌呤阿拉伯糖苷。     

抗丙肝药物维拉帕维的合成

以7-羟甲基-1-四氢萘酮和1-溴-4-氯-苯甲醛为起始原料,经14步反应合成了抗丙肝新药维拉帕维--甲基（2S）-1-【(2S,5S)-2-【9{2［（2S,4S）-1-（2R)-2-［（甲氧基羰基）氨基］-2-苯乙酰基-4-（甲氧基甲基）吡咯烷-2-基］-1H-咪唑 5 基} 1,11-二氢异色烯［4′,3′ :6,7］萘并［1,2-d］咪唑-2-基-5-甲基吡咯烷-1-基】-3-甲基-1-氧丁烷-2-基】氨基甲酸酯,总产率10.14%,其结构经¹H NMR和ESI-MS确证。     

新型N~6-哌嗪取代腺苷衍生物的合成及其抗肿瘤活性

以腺苷为母体,对其N6-位进行结构改造,首先经邻位双羟基保护,N6-位氯代,再在N6-位引入哌嗪环制得中间体2',3'-异丙叉-6-哌嗪嘌呤核苷(4);4与N-氯乙酰苯胺类似物(6a~6h)偶联后脱除邻位双羟基保护合成了8个新型的N6-哌嗪取代腺苷衍生物(8a~8h),其结构经1H NMR,13C NMR和HR-ESI-MS表征。采用MTT法研究了8a~8h对Hela肿瘤细胞的抑制活性。结果表明:大部分目标化合物对Hela肿瘤细胞具有较好的抑制活性,其中2-{4-[9-(3,4-二羟基-5-羟甲基-四氢呋喃-2-基)-9H-嘌呤-6-基]-哌嗪-1-基}-N-(3-氟苯基)-乙酰胺(8e)的活性最好,IC50为21.74μmol·L-1。     

A new, non-iterative asymmetric synthesis of long-chain 1,3-polyols

A new approach to the asymmetric synthesis of pentadeca-1,3,5,7,9,11,13,15-octols and their derivatives is presented. It is based on the Sharpless asymmetric dihydroxylation (AD) of 4,4'-methylene[(1R,1'S,6R,6'S)-6-acetoxycyclohept-3-en-1-yl]bis(4-methoxybenzoate) (9), derived from a double [3+4] cycloaddition of the 1,1,3-trichloro-2-oxyallyl cation with 2,2'-methylenedifuran (1). The diol (-)-10, obtained in 98.4% ee from 9 with "AD-mix-beta(5x), was oxidised into (2R and 2S,4S,6R)-tetrahydro-2-hydroxy-6-((4S,6S)-(6-hydroxy-4-[(4-methoxybenzoyl)oxy]cyclohept-1-en-1-yl)-2-oxopropyl)-2H-pyran-4-yl 4-methoxybenzoates ((-)-18). By the combinations of Evans' anti and Nasaraka's syn reductions of aldol (-)-18 with the double Mitsunobu reaction, 16 diastereomeric pentadeca-1,3,5,7,9,11,13,15-octols and analogues can be obtained, in principle, with high enantio- and diastereoselectivities.     

A stereoselective synthesis of xylitol

Rel-(2S, 3R, 4R)- (6) and rel-(2R,3R,4R)- (7) 1,2,5-triacetoxy-3,4-epoxypentanes have been obtained in seven steps starting from cyclopentadiene. Both diastereoisomers afford xylitol pentaacetate (8) selectively upon epoxide cleavage with acetate ion. In the case of (6), rel-(1s,3R,4r,5S)-3,-bisacetoxymethyl-1-methyl-2,6,7-trioxabicyclo- [2.2.1]heptane (11) has been isolated and characterised as an intermediate in the reaction.     

计算机辅助设计新型人脂肪酸合酶抑制剂及其抗肿瘤活性

以Orlistat为先导化合物,利用AutoDock进行计算机模拟对接,在对接结果中选择能量较低的6个结构进行合成与抗肿瘤活性筛选。以orlistat为原料,经2步反应制得苄基(2S,3S,5S)-2-己基-3,5-二羟基十六酸酯(2); 再经4步反应获得(3S,4S)-3-己基-4-［(S)-2-羟基十三烷基］氧杂环丁烷-2-酮(5); 5在EDCI作用下与酸经缩合反应合成了4个计新型人脂肪酸合酶抑制剂（6a~6d）,其中6b~6d为新化合物,其结构经¹H NMR, ¹³C NMR 和HR-MS（ESI）表征。体外初步活性测试表明：(S)-1-［(1S,2S)-3-己基-4-氧代氧杂环丁烷-2-基］十三烷-2-烟酸酯（6a）对MDA-MB-231细胞有较好的抑制作用,其IC₅₀为11.72 μmol·mL^-1,优于Orlistat(21.5 μmol·mL^-1)。     

Stereoselective synthesis of optically active disilanes and selective functionalization by the cleavage of silicon-naphthyl bonds with bromine

Optically active disilanes with one chiral silicon center, (R)-1,2-dimethyl-1-(naphth-1-yl)-1,2,2-triphenyldisilane and (R)-1,2,2-trimethyl-2-(4-methoxynaphth-1-yl)-1-(naphth-1-yl)-1-phenyldisilane, were obtained by the reaction of (S)-methyl(naphth-1-yl)phenylchlorosilane (> 99% ee) with methyldiphenylsilyllithium or by the reaction of methyldiphenylchlorosilane with optically active (S)-methyl(naphth-1-yl)phenylsilyllithium and by the reaction of (S)-methyl(naphth-1-yl)phenylchlorosilane (> 99% ee) with dimethyl(4-methoxynaphth-1-yl)silyllithium. Under the optimized conditions, the reactions proceeded with almost complete inversion for the cholorosilanes and retention for the silyl anions. Optically active disilanes with two chiral centers, (1R,2R)-1,2-dimethyl-1,2-di(naphth-1-yl)-1,2-diphenyldisilane and (1S,2S)-1,2-di(4-methoxynaphth-1-yl)-1,2-dimethyl-1,2-diphenyldisilane, were obtained in high optical purity by the reactions of corresponding optically active halogenosilanes (Cl or F) with optically active silyllithiums. The silicon-silicon bond and the silicon-naphthyl bond of (R)-1,1,2-trimethyl-1,2-di(naphth-1-yl)-2-phenyldisilane and (1R,2R)-1,2-dimethyl-1,2-di(naphth-1-yl)-1,2-diphenyldisilane were cleaved without selectivity on bromination. The silicon-(4-methoxynaphth-1-yl) bond of (R)-1,2,2-trimethyl-2-(4-methoxynaphth-1-yl)-1-(naphth-1-yl)-1-phenyldisilane was regiospecifically cleaved, followed by the stereoselective cleavage of the remaining chiral silicon-naphthyl bond (94% inversion). Although the silicon-(4-methoxynaphth-1-yl) bonds of (1S,2S)-1,2-di(4-methoxynaphth-1-yl)-1,2-dimethyl-1,2-diphenyldisilane (> 99% ee) were regioselectively cleaved without silicon-silicon bond scission, remarkable racemization could not be avoided during the one-pot reaction.     

Chemoenzymatic synthesis of phosphocarnitine enantiomers

Racemic phosphocarnitine 3 has been synthesized starting from diethyl 3-chloro-2-oxopropanephosphonate 4 in three steps involving reduction of 4 to the corresponding 2-hydroxyphosphonate 5, conversion of the latter to phosphonic acid 6, and final reaction with trimethylamine, affording the trimethylammonium salt of 3. Baker's yeast reduction of 4 and enzymatic kinetic resolution of (+/-)-5 afforded the enantiomerically pure precursors of phosphocarnitine, (R)-(+)-5 and (S)-(-)-5, which were converted to (S)-(-)- and (R)-(+)-phosphocarnitine 3, respectively.     

一个简捷、高效合成松叶蜂性信息素的方法

以从甾体皂甙元降解的废弃物获取的(4R)-甲基-5-溴戊酸甲酯(4)为起始原料, 通过4与正庚基溴化镁选择性的偶联反应, 经关键合成中间体(4S)-甲基溴代十二烷(7)分别以52%和49%的总收率合成了松叶蜂性信息素(2S,3S,7S)-3,7-二甲基十五-2-醇乙酸酯(2)和丙酸酯(3).     

Cyclobutanones through SNi' ring closure, a mechanistic study

Mechanistic studies on the intramolecular nucleophilic substitution with allylic rearrangement (SNi' reaction) and a new stereoselective access to substituted cyclobutanones are reported. 4,4-Dialkyl-5-oxohex-2E-en-1-yl methanesulfonates 4 were converted to 2,2-dialkyl-3-vinylcyclobutanones 6 by SNi' ring closure. The stereochemical analysis of the reaction was achieved through ring closure of (6S)-6-chloro-3,3-diethylhept-4E-en-2-one (S)-17, defined by the absolute configuration of C(6), leading to (3S)-2,2-diethyl-3-(prop-1E-en-1-yl)cyclobutanone (S)-(E)-18 and (3R)-2,2-diethyl-3-(prop-1Z-en-1-yl)cyclobutanone (R)-(Z)-18, in a ratio of 85:15, with almost complete transfer of chirality (>97%). The absolute configuration of (S)-17 was determined by X-ray diffraction analysis of the camphanoate derivative 16. The absolute configuration of the cyclobutanone products (S)-(E)-18 and (R)-(Z)-18 was determined by Raman optical activity spectroscopy. Comparison of the absolute configuration of (S)-17 and the resulting (E)- and (Z)-cyclobutanones 18 allowed the conclusion that the SNi' reaction proceeds with syn geometry relative to the leaving group.     

New synthetic strategy for preparation of the anticoagulant drug Rivaroxaban via an asymmetric Henry reaction

A new synthetic approach towards the anticoagulant drug (S)-Rivaroxaban was described. This reaction sequence involved six steps overall, starting from commercially available and inexpensive N-(4-aminophenyl)morpholin-3-one. The stereogenic centre was introduced by an asymmetric Henry reaction catalysed by the complex of copper(II) acetate and (2R,5S)-2-(pyridine-2-yl)imidazolidine-4-one with 87% ee. The individual reaction steps proceeded with high yields and did not require any unusual or expensive reagents.